DEVELOPMENT OF RESISTANCE TO 9-NITRO-CAMPTOTHECIN BY HUMAN LEUKEMIA U-937 CELLS IN-VITRO CORRELATES WITH ALTERED SENSITIVITIES TO SEVERAL ANTICANCER DRUGS
P. Pantazis et al., DEVELOPMENT OF RESISTANCE TO 9-NITRO-CAMPTOTHECIN BY HUMAN LEUKEMIA U-937 CELLS IN-VITRO CORRELATES WITH ALTERED SENSITIVITIES TO SEVERAL ANTICANCER DRUGS, Anti-cancer drugs, 5(4), 1994, pp. 473-479
We have recently reported that exposure of human leukemia U-937 cells
to progressively increasing concentrations of 9-nitro-camptothecin (9N
C) resulted in cell sublines exhibiting various levels of resistance t
o 9NC. Here, we report responses of wild-type (U-937/wt) and 9NC-resis
tant (U-937/CR) cells to various anticancer cs used extensively in can
cer chemotherapy. U-937/CR cells were more sensitive than U-937/wt cel
ls to several commonly used drugs of diverse origin including the topo
isomerase II-directed drugs amsacrine, etoposide and daunorubicin; the
vinca alkaloid vincristine; and the antimetabolite methotrexate. No r
esponses were induced by carmustine in either cell type, whereas simil
ar responses were induced by cytarabine. The sensitivity to the drugs
was investigated by monitoring cell proliferation, by determining cell
cycle perturbations assessed by flow cytometry analysis of DNA conten
t and by microscopy of stained cells. The results in this report indic
ate that development of 9NC resistance by the U-937 cells is accompani
ed by increased sensitivities to other anticancer drugs in vitro and v
ery likely in vivo.